Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02833467 | Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA | unknown | — | 45 | Peking University People's HospitalOTHER | 0 | Aug 28, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 |
| clinicaltrials |
| NCT04029350 | Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M(ALTN-03) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04063449 | Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC | unknown | N/A | 170 | Dong WangOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04063462 | Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04059874 | Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate | unknown | Phase 1 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT03972189 | Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 111 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT04058704 | A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy(SMART) | unknown | Phase 3 | 296 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT01823003 | Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases(sbrtlungfff) | unknown | Phase 2 | 67 | Institut Català d'OncologiaOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04037150 | Circulating DNA in Surgically Treated NSCLC | unknown | — | 100 | Helsinki University Central HospitalOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT03710616 | A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals | unknown | — | 700 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT04023617 | A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC | unknown | Phase 2 | 72 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT03334071 | Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients(EMBRACE) | unknown | N/A | 100 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT04007835 | Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI | unknown | N/A | 120 | Guangdong Association of Clinical TrialsOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03553485 | Effects of VNS on RT-induced Inflammation and Prognosis of Patients With NSCLC | unknown | N/A | 12 | Vrije Universiteit BrusselOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03992885 | Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. | unknown | Phase 3 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03987087 | A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC | unknown | Phase 2 | 68 | Guizhou Medical UniversityOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03244605 | Efficacy Study of Comprehensive Rehabilitation Program in Postoperative NSCLC Patients | unknown | Phase 3 | 236 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT03372694 | Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients | unknown | Phase 3 | 354 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT03983811 | Adjuvant Chemotherapy With or Without Intercalated Icotinib | unknown | N/A | 174 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jun 12, 2019 | clinicaltrials |
| NCT03726736 | Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC(ACWDVDFPTAN) | unknown | Phase 1 / Phase 2 | 97 | Yong FangOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03062800 | Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) | unknown | Phase 2 | 232 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03454685 | The Role of Microbiota on the Development of Lung Cancer | unknown | — | 100 | Xiaorong DongOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03724604 | NSE/Alb as a Prognostic Biomarker for Lung Cancer(NARPBLC) | unknown | — | 202 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT03938012 | Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma | unknown | — | 80 | National University Hospital, SingaporeOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03647956 | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | unknown | Phase 2 | 40 | The University of Hong KongOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03916913 | TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC | unknown | N/A | 85 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03911193 | CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation(CABinMET) | unknown | Phase 2 | 25 | Fondazione Ricerca TraslazionaleOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT03905317 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | unknown | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03428022 | Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC(AFLC) | unknown | Phase 3 | 54 | Shenzhen People's HospitalOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03903887 | A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT02764606 | CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer(CANPOS) | unknown | — | 250 | Hospices Civils de LyonOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT03374280 | Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC | unknown | Phase 2 | 178 | Guangzhou Medical UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT03886441 | Prevention of Locally Advanced NSCLC Radiotherapy Pneumonia by Inhaling Beclomethasone Propionate | unknown | Phase 2 | 194 | Tongji UniversityOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT03884192 | Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC(CONSIST) | unknown | Phase 3 | 162 | Shandong Cancer Hospital and InstituteOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03874000 | Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients(SMART) | unknown | Phase 2 | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03871205 | Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | unknown | Phase 1 | 30 | Shenzhen People's HospitalOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03077854 | Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial | unknown | N/A | 64 | National Taiwan University HospitalOTHER | 1 | Mar 11, 2019 | clinicaltrials |
| NCT03856697 | Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation | unknown | Phase 3 | 406 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02771314 | Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC | unknown | Phase 2 | 48 | Hellenic Oncology Research GroupOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03840408 | Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer | unknown | N/A | 1,753 | Shanghai 10th People's HospitalOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02726568 | High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 19, 2019 | clinicaltrials |
| NCT03300115 | Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC | unknown | Phase 2 | 222 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 19, 2019 | clinicaltrials |
| NCT03838588 | The Tracking Molecular Evolution for NSCLC (T-MENC) Study | unknown | — | 200 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03823807 | A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC | unknown | Phase 2 | 300 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | unknown | Phase 1 | 85 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT03811054 | The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 60 | Beijing Chest HospitalOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT02480634 | Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer | unknown | Phase 4 | 280 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Jan 16, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Aug 28, 2019source: clinicaltrials